_19-sean-scott-vp-amp-gm-clinical-genomics-qiagen-bioinformatics-session-cancer-dx.jpg "19. Sean Scott, VP & GM, Clinical Genomics, QIAGEN Bioinformatics- Session: Cancer Dx from ngs terms Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 9 min 17 sec
✓ Published: 16-Feb-2016
✓ Published: 16-Feb-2016
Description:
Scaling NGS Test Interpretation and Reporting In OncologynnThe interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limiting factor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefl
Scaling NGS Test Interpretation and Reporting In OncologynnThe interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limiting factor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefl
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_ngs-crypto-blockchain-mining-explained-short.webp "Learn More About NGS Crypto's Blockchain Mining Packages Offering 6-16% Per Annum. Packages Available Over 2, 3 or 5 years, No Management Fees, Returning 100% Of Your Initial Investment Upon Completion. Minimum investment amounts apply – to find full terms & conditions please visit https://ngscrypto.com/terms-conditions.nnDisclaimer:nnThe information in this video is for educational purposes and is general information only. It should not be taken as constituting financial advice from the v")
_weapons-of-mass-migration-live-panel-qampa.webp "Crossroads with JOSHUA PHILIPP")
_next-generation-sequencing-acronyms-and-terms-seq-it-out-15.webp "Thermo Fisher Scientific")
_ngs-crypto-blockchain-mining-specialists.webp "NGS Crypto is an Australian owned & operated Blockchain Mining Company. We offer members the opportunity to earn between 6-16% per annum, fixed rate returns. Packages available over 2, 3, 5, 7 & 10 year terms, no management fees, returning 100% of your initial capital at the end of your term. Terms & Conditions apply, for more information about NGS Crypto, or to speak with us further, please contact us via phone on 1300 001 647 or visit our website https://ngscrypto.com nnDisclaimer:")
_sequencing-coverage-124-gene-coverage-amp-read-depth-124-sequencing-coverage-for-ngs-experiment-124.webp "BMH learning")
⏲ 2 minutes 14 seconds 👁 936
_19-sean-scott-vp-amp-gm-clinical-genomics-qiagen-bioinformatics-session-cancer-dx.webp "Scaling NGS Test Interpretation and Reporting In OncologynnThe interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limiting factor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefl")
⏲ 9 min 17 sec ✓ 16-Feb-2016
_ngs-report-in-cancer-what-to-know-in-layman39s-terms.webp "Dr Sudha S Murthy")
_3-next-generation-sequencing-ngs-coverage-amp-sample-quality-control.webp "Applied Biological Materials - abm")
⏲ 6 minutes 39 seconds 👁 46.9K
_ngs-crypto-blockchain-mining-explained-short.jpg)
_weapons-of-mass-migration-live-panel-qampa.jpg)
_next-generation-sequencing-acronyms-and-terms-seq-it-out-15.jpg)
_ngs-crypto-blockchain-mining-specialists.jpg)
_sequencing-coverage-124-gene-coverage-amp-read-depth-124-sequencing-coverage-for-ngs-experiment-124.jpg)
_ngs-report-in-cancer-what-to-know-in-layman39s-terms.jpg)
_3-next-generation-sequencing-ngs-coverage-amp-sample-quality-control.jpg)
![[+]](/images/menu.gif){kind=small}